In vivo and in vitro evaluation of novel μ-opioid receptor agonist compounds
详细信息 查看全文
- 作者：Yoshiaki Nikaido<sup>asup> ; Aya Kurosawa<sup>asup> ; Hitomi Saikawa<sup>asup> ; Satoshi Kuroiwa<sup>asup> ; Chiharu Suzuki<sup>asup> ; Nobuo Kuwabara<sup>bsup> ; Hazime Hoshino<sup>csup> ; Hideaki Obata<sup>csup> ; Shigeru Saito<sup>csup> ; Tamio Saito<sup>dsup><sup> ; sup><sup>esup> ; Hiroyuki Osada<sup>esup> ; Isao Kobayashi<sup>fsup> ; Hideki Sezutsu<sup>fsup> ; Shigeki Takeda<sup>asup><sup> ; sup><sup>stakeda@gunma-u.ac.jp" class="auth_mail" title="E-mail the corresponding authorsup>
- 关键词：DAMGO ; (2S)-2-[[2-[[(2R)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl] amino]propanoyl]amino]acetyl]-methylamino]-N-(2-hydroxyethyl)-3-phenylpropanamide ; DMSO ; Dimethyl sulfoxide ; DsRed ; Discosoma sp. red fluorescent protein ; EGFP ; enhanced green fluorescent protein ; Gal4 ; the yeast transcription activator protein ; GPCRs ; G protein-coupled receptors ; GUM1 ; 2-[({2-[2-ethyl-4-(2-methoxyphenyl)-2-methyl-2H-3 ; 4 ; 5 ; 6- tetrahydro pyran-4-yl]ethyl}amino)methyl]phenol hydrochloride ; PWL ; paw withdrawal
- 刊名：European Journal of Pharmacology
- 出版年：2015
- 出版时间：15 November 2015
- 年：2015
- 卷：767
- 期：Complete
- 页码：193-200
- 全文大小：989 K
文摘
Opioids are the most effective and widely used drugs for pain treatment. Morphine is an archetypal opioid and is an opioid receptor agonist. Unfortunately, the clinical usefulness of morphine is limited by adverse effects such as analgesic tolerance and addiction. Therefore, it is important to study the development of novel opioid agonists as part of pain control. The analgesic effects of opioids are mediated by three opioid receptors, namely opioid μ-, δ-, and κ-receptors. They belong to the G protein-coupled receptor superfamily and are coupled to G<sub>isub> proteins. In the present study, we developed a ligand screening system to identify novel opioid μ-receptor agonists that measures [<sup>35sup>S]GTPγS binding to cell membrane fractions prepared from the fat body of transgenic silkworms expressing μ-receptor-G<sub>i1sub>α fusion protein. We screened the RIKEN Natural Products Depository (NPDepo) chemical library, which contains 5848 compounds, and analogs of hit compounds. We successfully identified a novel, structurally unique compound, that we named GUM1, with agonist activity for the opioid μ-receptor (EC<sub>50sub> of 1.2 µM). The Plantar Test (Hargreaves' Method) demonstrated that subcutaneous injection of 3 mg/kg of GUM1 into wild-type rats significantly extended latency time. This extension was also observed in a rat model of morphine tolerance and was inhibited by pre-treatment of naloxone. The unique molecular skeleton of GUM1 makes it an attractive molecule for further ligand–opioid receptor binding studies.